Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Jul 1;149(1):186-190.
doi: 10.1002/ijc.33554. Epub 2021 Mar 26.

Renal function outcomes in patients with muscle-invasive bladder cancer treated with neoadjuvant pembrolizumab and radical cystectomy in the PURE-01 study

Francesco Trevisani  1 , Federico Di Marco  1 , Daniele Raggi  2 , Arianna Bettiga  1 , Riccardo Vago  1 , Alessandro Larcher  1 , Alessandra Cinque  1 , Andrea Salonia  1   3 , Alberto Briganti  1   3 , Umberto Capitanio  1 , Andrea Necchi  2 , Francesco Montorsi  1   3
Affiliations
Clinical Trial

Renal function outcomes in patients with muscle-invasive bladder cancer treated with neoadjuvant pembrolizumab and radical cystectomy in the PURE-01 study

Francesco Trevisani et al. Int J Cancer. .

Abstract

The use of pembrolizumab has been largely accepted in several advanced types of cancers. PURE 01 study (NCT02736266) enrolled consecutively 143 patients with muscle-invasive bladder cancer who received 3 cycles of pembrolizumab 200 mg every 3 weeks before planned radical cystectomy (RC). Clinical, pathological and laboratory data were collected to investigate the relationship between renal function, immunotherapy and cancer-related outcomes. Serum creatinine and estimated glomerular filtration rate (eGFR) using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine-equation 2009 were reported at baseline and after every cycle of pembrolizumab; the T stage from clinical classification TNM (cTNM) was stated before the treatment. Our analysis did not demonstrate a significant impairment of eGFR after any cycle of pembrolizumab, neither in the overall cohort nor in subgroups considering the T stages or the CKD G-categories according to K-DIGO 2012 classification. In conclusion, in neoadjuvant setting before RC our results suggest that pembrolizumab administration is safe for renal function preservation.

Keywords: acute kidney injury; bladder cancer; chronic kidney disease; immunotherapy; neoadjuvant therapy; renal function.

PubMed Disclaimer

References

REFERENCES

    1. Peláez Bejarano A, Montero Pérez O, Inoriza Rueda A, Garrido Martínez MT. Interstitial nephritis with pembrolizumab: a case report and review. J Oncol Pharm Pract. 2020. Online ahead of print.
    1. Cortazar FB, Kibbelaar ZA, Glezerman IG, et al. Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study. J Am Soc Nephrol. 2020;31:435-446.
    1. Mroue A, Moujaess E, Kourie HR, Azar H, Finianos S, Chelala D. Exploring the knowledge gap of immune checkpoint inhibitors in chronic renal failure: a systematic review of the literature. Crit Rev Oncol Hematol. 2021;157:103169.
    1. Necchi A, Raggi D, Giannatempo P, et al. Can patients with muscle-invasive bladder cancer and fibroblast growth factor receptor-3 alterations still be considered for neoadjuvant pembrolizumab? A comprehensive assessment from the updated results of the PURE-01 study. Eur Urol Oncol. 2020;77(4):439-446.
    1. Necchi A, Raggi D, Gallina A, et al. Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies. Eur Urol. 2020;77:439-446.

Publication types

MeSH terms

Substances

Associated data